Back

Silencing TTR, distinct signals: safety profiles of small interfering RNA therapies in amyloidosis

11 May 2026 (10:30 - 11:15)
Organised by: Logo
Congress Presentation Part of: Advances in amyloidosis and hypertrophic cardiomyopathy: from diagnosis to treatment Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Mrs Joyce Gu

Erie (United States of America)

6 More presentations in this session

Presentation thumbnail
Acute administration of EDG-15400, a novel cardiac sarcomere modulator, improves left ventricular compliance and cardiac reserve in a genetic mini-pig model of HCM with relevance to HFpEF
Doctor C. Emter (Boulder, US)
Abstract Slides Video
Presentation thumbnail
Prevalence and prognostic implications of frailty and other geriatric conditions in patients with transthyretin amyloid cardiomyopathy. The AMYLO-FRAIL study.
Doctor M. Antunez-Ballesteros (Coruna, A, ES)
Abstract Slides Video
Presentation thumbnail
Tafamidis in women with wild-type transthyretin cardiac amyloidosis: an international cohort study
Doctor P. Debonnaire (Brugge, BE)
Abstract Slides Video
Presentation thumbnail
Treatment with transthyretin-lowering RNA interference therapeutics is not associated with ocular or other clinical events due to vitamin A reduction: pooled analysis of vutrisiran and patisiran data
Doctor M. Maurer (New York, US)
Abstract Slides Video
Presentation thumbnail
Transthyretin gene silencing therapy in Val50Met familial amyloid polyneuropathy with associated cardiomyopathy
Doctor P. Monteiro (Porto, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Advances in amyloidosis and hypertrophic cardiomyopathy: from diagnosis to treatment

The Event

Event poster

Heart Failure 2026

11 May 2026 10:30 CET
You may be interested in
thumbnail
Congress Presentation
Safety profile of acoramidis in cardiac amyloidosis: insights from post-marketing pharmacovigilance data
11 May 2026
thumbnail
Congress Presentation
Update on RNAi therapy in hATTR amyloidosis.
22 May 2022
thumbnail
Congress Presentation
What have we learned? Long-term safety and efficacy of inclisiran
27 August 2023
thumbnail
Congress Presentation
Tolerability of continued treatment with ATTR depleter ALXN2220 in the open-label extension of Phase 1 study NI006-101
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources